Tempus AI Inc (TEM.O)

[Malvolio]

Zitat

 

July 9 (Reuters) - Wall Street brokerages started covering SoftBank Group-backed Tempus AI (TEM.O), opens new tab on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits. The Chicago, Illinois-based company sells genomic diagnostics tests across oncology and other areas, including neuropsychiatry, radiology and cardiology to clinicians and hospital systems. Seven brokerages, including J.P.Morgan, Morgan Stanley, BofA Global Research and Stifel initiated coverage with a "buy" or "overweight" rating, with the highest price target of $50 by TD Cowen. The brokerages, which were underwriters for Tempus' initial public offering, issued their first ratings after the so-called "quiet period" ended on Tuesday. The upbeat ratings lifted the shares of the company as much as 7% to $35.75. The stock has lost 17.5% since the closing on June 14, its debut day, till the end of trade on Monday.

 

J.P.Morgan forecasts roughly 33% revenue growth for Tempus through 2027. It expects the company to turn a core profit by the second half of 2025.  Tempus AI's net loss widened to $289.8 million in 2023 from $214.1 million a year earlier, while total revenue jumped 65.8% to $531.8 million. However, revenue from its AI applications business constituted about 1% of the total revenue, according to a regulatory filing, opens new tab. Tempus described its AI applications revenue as "immaterial".

 

The "uniquely combined clinical genomic data, which the company has successfully monetized in the form of licensing agreements with pharma and biotech customers" separates Tempus from rivals, according to J.P.Morgan. Morgan Stanley expects revenue growth of 27% through 2028, and expects the company to break-even on core profit by 2027. The brokerage noted that if competitors tried to grow their own database, it would "likely prove to be costly, cumbersome and time-consuming efforts". BofA Global Research said there is space for Tempus to further expand the scope of the existing relationships with biotech and large pharma companies as well as increase the number of new customers.

 

https://www.reuters.com/technology/artificial-intelligence/wall-street-analysts-bullish-genetic-testing-firm-tempus-ai-2024-07-09/

 

 

Zitat

 

Company Information

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

 

https://www.reuters.com/markets/companies/TEM.O

 

Google setzt auf Tempus AI: Beeindruckender Börsenstart für das aufstrebende KI-Unternehmen | 17.06.24 | finanzen.ch

 

Tempus AI war heute (10.07.2024) auch Thema im WELT AAA Podcast:

Eine neue KI-Healthcare-Aktie und Angst vor Concentration-Bubble

 

https://www.tempus.com/

 

https://www.comdirect.de/inf/aktien/US88023B1035

 

Ist leider im Moment nur an der NASDAQ handelbar.

 

 

[Tordal]

Danke für die Vorstellung. Hab mir den AAA-Podcast direkt angehört. klingt auf jeden Fall interessant und werde ich weiter beobachten.  

[albr]

hatte mir vor ein paar Tagen ein paar Aktien ins Depot gelegt  grundsätzlich klasse Idee ! Umsatz ist nicht zu verachten... mal schauen; KI wird nunmal das grosse Ding, nur ist die Frage wer die ganz grossen Gewinner sein werden ?? (ich rede von 20 Jahren und mehr)

[Malvolio]

Habe mir auch mal ein paar Aktien gegönnt .... ich finde auch, dass es sehr interessant klingt .... wollen wir mal abwarten, was dabei rauskommt.